Travere officer files notice for $3.3M stock sale

An officer of Travere Therapeutics filed a Rule 144 notice to potentially sell up to 50,508 shares of TVTX common stock, largely from vested equity awards.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) officer Christopher Cline filed a notice of proposed sale of Travere common stock under Rule 144. The filing contemplates the sale of up to 50,508 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 15, 2026.

The shares to be sold include 20,000 shares related to an Exercise of Stock Options dated September 15, 2026 and 30,508 shares acquired from Restricted Stock Units granted May 9, 2020 and vesting through September 1, 2026. The notice also reports a prior sale of 642 shares on September 2, 2026.

Key Figures

Shares proposed for sale under Rule 144: 50,508 shares Market value of shares in notice: $3,322,921.32 Shares from stock option exercise: 20,000 shares +4 more

7 metrics

Shares proposed for sale under Rule 144 50,508 shares Travere Therapeutics common stock covered by the notice

Market value of shares in notice $3,322,921.32 Aggregate market value associated with the 50,508 shares

Shares from stock option exercise 20,000 shares Common stock tied to Exercise of Stock Options dated September 15, 2026

Shares from vested RSUs 30,508 shares Common stock acquired from Restricted Stock Units granted May 9, 2020

Recent shares sold 642 shares Common stock sold on September 2, 2026 during the past three months

Proceeds from recent sale $42,609.54 Total for 642 shares sold on September 2, 2026

Notice date September 15, 2026 Date of the Rule 144 notice

Key Terms

Rule 144, restricted stock units, Exercise of Stock Options, Executive Financial Services

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Travere Therapeutics (TVTX)?

It discloses that officer Christopher Cline filed a notice under Rule 144 to potentially sell up to 50,508 shares of Travere Therapeutics common stock through Morgan Stanley Smith Barney LLC, with a notice date of September 15, 2026.

How many TVTX shares are proposed to be sold in this Form 144?

The notice covers a proposed sale of up to 50,508 shares of Travere Therapeutics common stock, to be transacted through Morgan Stanley Smith Barney LLC on or after September 15, 2026.

What is the source of the Travere Therapeutics (TVTX) shares to be sold?

The filing states that 20,000 shares are tied to an Exercise of Stock Options dated September 15, 2026, and 30,508 shares were acquired upon the vesting of restricted stock units granted on May 9, 2020 and vesting through September 1, 2026.

What is the reported market value of the TVTX shares in this Form 144?

The Form 144 lists an aggregate market value of $3,322,921.32 for the 50,508 shares of Travere Therapeutics common stock covered by the notice, in connection with the proposed Rule 144 sale.

Were any Travere Therapeutics (TVTX) shares sold in the prior three months?

Yes. The filing reports that 642 shares of Travere Therapeutics common stock were sold on September 2, 2026 for a total of $42,609.54 during the past three months.

Who is the beneficial owner in this Travere Therapeutics (TVTX) Form 144?

The person for whose account the securities are to be sold is Christopher Cline, identified as an officer of Travere Therapeutics, Inc., with the issuer’s address at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:45 PM Accepted by SEC EDGAR 09/15/2026 - 04:44 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001943192
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER CLINE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50508	3322921.32	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			20000	09/15/2026	Cash
Common	05/09/2020	Restricted Stock Units	Issuer			30508	05/09/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER CLINE 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/02/2026	642	42609.54

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 05/09/2020 through 09/01/2026.
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Cline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)